A landmark clinical trial of semaglutide, published in 2021, found that participants experienced an average of 15% weight loss over the course of 68 weeks while those on placebo lost 2%
NIH working group report: innovative research to improve maintenance of weight loss
Medications for Cardiovascular Conditions Diuretics , (e.g., Furosemide) often used to manage edema or hypertension, can lead to dehydration, a concern given semaglutides tendency to cause vomiting and diarrhea
The same principle applies to compounded semaglutide storage , tirzepatide refrigeration requirements , and virtually all reconstituted peptides
Importantly, the FDA labels for semaglutide products note that these medications have not been studied in patients with severe gastrointestinal disease, including severe gastroparesis, and are not recommended for use in these populations